tno155
Small moleculeexperimental
Clinical trial activity
7 trials · 4 clinical orgs · 0 marketing orgs
Phase 1
7
Phase 2
2
Phase 3
0
Phase 4
0
Earliest trial started May 31, 2017 (NCT03114319)
Timeline
2010s
- Jan 1, 2017
Earliest Phase 1 Sponsor(trial)
Indications
Studied for
- Carcinoma, Non-Small-Cell Lung · Phase 1/Phase 2
- Colorectal Neoplasms · Phase 1/Phase 2
- Esophageal Neoplasms · Phase 1
- Esophageal Squamous Cell Carcinoma · Phase 1
- Gastrointestinal Stromal Tumors · Phase 1
- Head and Neck Neoplasms · Phase 1
- Kidney Failure, Chronic · Phase 1
- Liver Diseases · Phase 1
- Lung Neoplasms · Phase 1/Phase 2
- Melanoma · Phase 1
- Neoplasm Metastasis · Phase 1/Phase 2
- Neoplasms · Phase 1/Phase 2
- Squamous Cell Carcinoma of Head and Neck · Phase 1
Mechanism of action
- GTPase KRasINHIBITOR
KRAS inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- tno155
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05541159 | Phase 1 | Mar 20, 2023 | Novartis, Pharmaceutical Research Associates, Inc. (PRA) |
| NCT05490030 | Phase 1 | Feb 27, 2023 | Novartis, Pharmaceutical Research Associates, Inc. (PRA) |
| NCT04699188 | Phase 1/Phase 2 (Phase 2) | Feb 24, 2021 | Novartis |
| NCT04294160 | Phase 1 | May 26, 2020 | Novartis |
| NCT04330664 | Phase 1/Phase 2 (Phase 2) | Apr 30, 2020 | Bristol-Myers Squibb, Mirati Therapeutics Inc., Novartis |
| NCT04000529 | Phase 1 | Jul 5, 2019 | Novartis |
| NCT03114319 | Phase 1 | May 31, 2017 | Novartis |
Showing 7 of 7 trials
Page 1 / 1
Organizations
Research & Development (4)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Novartis | For profit | 7 | 6 | 2 | 2017 |
| Pharmaceutical Research Associates, Inc. (PRA) | For profit | 2 | 0 | 1 | 2023 |
| Bristol-Myers Squibb | For profit | 1 | 0 | 1 | 2020 |
| Mirati Therapeutics Inc. | For profit | 1 | 1 | 1 | 2020 |
4 organizations
Page 1 / 1